The case and the parties
The case is Hologic, Inc. v. Siemens Healthineers AG, No. 1:26-cv-01470 (D. Del.). The complaint was filed on November 16, 2026, with a jury demand. It says Hologic is a Delaware corporation headquartered in Marlborough, Massachusetts. It says Siemens Healthineers AG and Siemens Healthcare GmbH are organized under the laws of Germany, with principal places of business in Forchheim and Erlangen, and that Siemens Medical Solutions USA, Inc. is a Delaware corporation with its principal place of business in Malvern, Pennsylvania. It refers to the three defendants together as "Siemens."
The complaint alleges, on information and belief, that Siemens Healthineers AG is the parent of Siemens Healthcare GmbH and directs, controls, and/or participates in the manufacture and commercialization of the accused products; that Siemens Healthcare GmbH manufactures and/or has manufactured them in Germany and sells or supplies them for importation into the United States; and that Siemens Medical Solutions USA, Inc. imports, markets, offers for sale, sells, distributes, installs, services, and supports them in the United States. It says Siemens' FDA submissions identify Siemens Medical Solutions USA, Inc. as the U.S. importer and distributor of the system.
The accused system
The complaint defines the accused products as the Siemens MAMMOMAT B.brilliant digital mammography and breast tomosynthesis systems, including versions and configurations marketed with VA10 and VA11 software, and related configurations, components, X-ray tubes, X-ray tube assemblies, and accessories. The complaint says Siemens introduced the system in September 2023. It says that, according to Siemens, the X-ray tube moves continuously through a 50 degree angular range during tomosynthesis while the system acquires 25 projection images, and that during each X-ray pulse an electron beam is deflected so the focal spot on the anode moves in the direction opposite the tube's movement, making the focal spot appear stationary from outside the tube.
The complaint says the FDA cleared the system with VA10 through 510(k) K233539 on March 27, 2024, and cleared a second 510(k), K253678, on June 18, 2026, which it says adds or modifies functions including biopsy and dual-energy capabilities. It alleges, on information and belief, that the VA11 configuration keeps the B.brilliant hardware and the flying-focal-spot function relevant to infringement. It says at least two B.brilliant systems have been publicly identified as installed in the United States, one in Iowa and one in New Jersey.
The asserted patents
The complaint asserts five patents and says Hologic owns all right, title, and interest in each:
- U.S. Patent 8,457,282, "Method and System for Controlling X-Ray Focal Spot Characteristics for Tomosynthesis and Mammography Imaging," issued June 4, 2013, from Application No. 12/623,472, filed November 23, 2009.
- U.S. Patent 8,515,005, "Tomosynthesis With Shifting Focal Spot and Oscillating Collimator Blades," issued August 20, 2013, from Application No. 12/849,294, filed August 3, 2010, a continuation-in-part of the '282 patent's application.
- U.S. Patent 8,767,911, with the same title, issued July 1, 2014, from Application No. 13/966,606, filed August 14, 2013.
- U.S. Patent 9,502,148, with the same title, issued November 22, 2016, from Application No. 14/966,011, filed December 11, 2015.
- U.S. Patent 9,895,115, with the same title, issued February 20, 2018, from Application No. 15/357,857, filed November 21, 2016.
The complaint says the '282 patent's application claims priority to Provisional Application No. 61/117,453, filed November 24, 2008, and that each of the other four issued from a chain of continuation and continuation-in-part applications going back to that application. It says the patents address blur caused when the X-ray source moves during an exposure, with embodiments that move the focal spot opposite to the source's movement so the effective focal spot stays substantially fixed relative to the breast and/or detector, and that certain asserted claims also concern coordinated control of collimation during imaging.
The European proceedings
The complaint says European Patent No. EP 2 352 431 is the European counterpart to the '282 patent. It says Siemens Healthcare GmbH filed an opposition to that patent at the European Patent Office in May 2019, that the Opposition Division rejected the opposition, and that on February 14, 2024, the Technical Board of Appeal dismissed Siemens Healthcare GmbH's appeal and left the patent in force as granted, in case T 1762/21.
It says that after Siemens introduced the MAMMOMAT B.brilliant, Hologic sued Siemens Healthineers AG, Siemens Healthcare GmbH, and two other Siemens affiliates for infringement in the Düsseldorf Local Division of the Unified Patent Court, and that Siemens denied infringement and counterclaimed for revocation. It says that on June 10, 2026, in UPC_CFI_758/2024 and UPC_CFI_259/2025, that court rejected the validity challenge and found that the MAMMOMAT B.brilliant infringed the European patent. The complaint says U.S. infringement must be determined independently under U.S. law, and that it cites the European decision for the parties' history and Siemens' knowledge.
The counts
Each of the five counts alleges direct infringement under 35 U.S.C. 271(a), literally and/or under the doctrine of equivalents, by making, using, offering to sell, selling, and/or importing the accused products, along with induced infringement under 271(b) and contributory infringement under 271(c). The claims identified are at least claims 1, 2, 4, 5, 7, and 8 of the '282 patent; claims 1 to 4 and 6 to 18 of the '005 patent; claims 1 to 8 and 10 to 19 of the '911 patent; claims 1 and 3 to 18 of the '148 patent; and claims 1 and 3 to 20 of the '115 patent. The complaint says Exhibits F through J identify, by example, where each element of one or more claims of each patent is found in the accused products.
The inducement allegations point to manuals, training, technical support, installation, service, demonstrations, advertising, and marketing materials directed at customers and end users. The complaint alleges that the defendants have had actual knowledge of Hologic's related focal-spot patent rights at least since the 2019 European opposition, alleges on information and belief that they have had knowledge of the asserted patents through their patent-review, product-development, regulatory, and litigation activities, and alleges, also on information and belief, that Siemens Healthineers AG and Siemens Medical Solutions USA, Inc. learned of the European proceedings through their corporate affiliation with Siemens Healthcare GmbH. At a minimum, it alleges knowledge of the patents and of the infringement upon service of the complaint. It alleges that the infringement has been deliberate and, on information and belief, willful.
Jurisdiction, venue, and relief
The complaint alleges personal jurisdiction over Siemens Medical Solutions USA, Inc., and venue under 28 U.S.C. 1400(b), because it is incorporated in Delaware. For the two German defendants, it alleges personal jurisdiction because, on information and belief, they have purposefully directed activities toward Delaware and the United States relating to the accused products, including through their Delaware-incorporated U.S. affiliate, and in the alternative under Federal Rule of Civil Procedure 4(k)(2), with venue under 28 U.S.C. 1391(c)(3) because they are foreign entities.
The prayer asks for a declaration that the defendants have infringed and continue to infringe one or more claims of each asserted patent, directly and/or indirectly, literally and/or under the doctrine of equivalents, and that the infringement has been willful; a permanent injunction against making, using, offering for sale, selling, or importing into the United States products that infringe the asserted patents, including the accused products; damages adequate to compensate for the infringement, in no event less than a reasonable royalty, including supplemental damages for any post-verdict infringement, with prejudgment and post-judgment interest and costs; enhanced damages of up to three times the amount found under 35 U.S.C. 284; a declaration that the case is exceptional with attorneys' fees under 35 U.S.C. 285; costs and expenses; and other relief the court deems just and proper.
The related Delaware case
On November 13, 2026, Siemens Medical Solutions USA, Inc. sued Hologic, Inc. in the same court, No. 1:26-cv-01460, asserting U.S. Patent 8,284,894 against Hologic's mammography systems, including the Envision Mammography Platform. That complaint says its exemplary claim chart relies in part on a USPTO letter to the FDA about Hologic's request for patent term extension of the '282 patent, one of the five patents Hologic asserts here.
What to watch next
Watch for the defendants' answer or a Rule 12 motion, including any challenge to personal jurisdiction, and any order relating or coordinating this case with No. 1:26-cv-01460. The case can end at any time, including by settlement or voluntary dismissal.